A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors

Trial Profile

A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2013

At a glance

  • Drugs Docetaxel (Primary) ; Filgrastim; Gemcitabine; Pegfilgrastim
  • Indications Bladder cancer; Breast cancer; Gastric cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top